The United States of America, as Represented by the Secretary, Department of Health and Human Services

Hospital Clinic De Barcelona

British Columbia Cancer Agency Branch

Universität De Barcelona

Oslo University Hospital Hf

Julius-Maximilians-University of Wurzburg

The University of Arizona

University of Nebraska

Oregon Health & Science University

The Cleveland Clinic Foundation

University of Rochester

University of London

Mayo Foundation for Medical Education and Research

City of Hope

Julius-Maximilians-Universitaet Wuerzburg

Louis M Staudt

Erlend B Smeland

Elaine S Jaffe

Joseph M Connors

Lisa M Rimsza

George W Wright

German Ott

Jan Delabie

Dennis Weisenburger

Wing C Chan

Randy D Gascoyne

Kai Fu

Rita M Braziel

Andreas Rosenwald

Sandeep S Dave

Elias Campo Guerri

David William Scott

James Robert Cook

Wyndham H Wilson

Hans-Konrad Muller-Hermelink

Harald Holte

Richard I Fisher

Timothy C Greiner

Armando Lopez-Guillermo

Pedro Jares

Bruce Tan

George Wright

Raymond Tubbs

Chih-Jian Lih

Randy Gascoyne

Georg Lenz

Stein Kvaloy

Paul Michael Williams

Andrew T Lister

Anja Mottok

Timothy Greiner

Thomas M Grogan

Federico Bernal

Itziar Salaverria

Victor Moreno

Andreas Zettl

Julie Vose

T Andrew Lister

Stein Kvaløy

Lisa Rimsza

Christian Steidl

John I Powell

James Armitage

Thomas Miller

Silvia M Bea

Emilio Montserrat

Yibin Yang

Amanda L Whiting

Joo Song

Diego Villa

Rita Braziel

Pau Abrisqueta

Graham Slack

James R Cook

Dennis D Weisenburger

The present invention provides methods of determining a survival predictor score of a subject having mantle cell lymphoma (MCL). The present invention also provides methods of predicting the survival outcome of a subject having MCL and provides methods of selecting a treatment for a subject having MCL.

Evaluation of mantle cell lymphoma and methods related thereto

In embodiments of the invention, the invention provides a method for distinguishing between lymphoma types based on gene expression measurements. In embodiments, the invention distinguishes between PMBCL and DLBCL based on gene expression signatures, and can further distinguish between DLBCL subtypes. In embodiments of the invention, the distinctions are used in methods of treatment.

Method for determining lymphoma type and providing treatment

The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.

Method for subtyping lymphoma types by means of expression profiling

The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.

Survival predictor for diffuse large B cell lymphoma

Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.

Methods for identifying, diagnosing, and predicting survival of lymphomas

The invention provides methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention provides a microarray for obtaining gene expression data from a lymphoma sample. The invention also provides a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma, which is useful in developing an appropriate therapeutic approach.

The invention relates to peptide inhibitors of linear ubiquitin chain assembly complex (LUBAC) and to methods of treating diseases including activated B-cell like diffuse large B cell lymphoma (ABC DLBCL) and autoimmune or inflammatory disorders.

Inhibitors of the linear ubiquitin chain assembly complex (LUBAC) and related methods

Growing community of inventors

Bethesda, MD, United States of America

Louis M Staudt